S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Stock market today: World shares mostly lower as Congress averts a US government shutdown
Gold Could Be Heading for Record Highs - But How to Play It? (Ad)
Bank of Japan survey shows manufacturers optimistic about economy
Federal student loan payments are starting again. Here's what you need to know
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
Facing increasing pressure from customers, some miners are switching to renewable energy
How is This "Hidden Gem" Thriving in a Turbulent Market? (Ad)
Grant program for Black women entrepreneurs blocked by federal appeals court
The death toll in a collapsed gold mine in Zimbabwe expected to rise to 13, vice president says
NASDAQ:COLL

Collegium Pharmaceutical (COLL) Stock Forecast, Price & News

$22.35
-0.25 (-1.11%)
(As of 09/29/2023 08:52 PM ET)
Compare
Today's Range
$22.27
$22.65
50-Day Range
$21.55
$24.28
52-Week Range
$15.92
$30.22
Volume
323,400 shs
Average Volume
376,674 shs
Market Capitalization
$776.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.50

Collegium Pharmaceutical MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
58.8% Upside
$35.50 Price Target
Short Interest
Bearish
20.49% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.78
Upright™ Environmental Score
News Sentiment
1.02mentions of Collegium Pharmaceutical in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
17.34%
From $4.73 to $5.55 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

494th out of 968 stocks

Pharmaceutical Preparations Industry

232nd out of 452 stocks


COLL stock logo

About Collegium Pharmaceutical (NASDAQ:COLL) Stock

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

COLL Price History

COLL Stock News Headlines

Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Gold Could Be Heading for Record Highs - But How to Play It?
According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.
Which of These 3 Pharma Stocks Are a Buy?
COLL - Collegium Pharmaceutical, Inc.
Bausch Health Companies (BHC) Receives a Hold from Piper Sandler
See More Headlines
Receive COLL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Collegium Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

COLL Company Calendar

Last Earnings
8/03/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:COLL
Fax
N/A
Employees
207
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.50
High Stock Price Forecast
$36.00
Low Stock Price Forecast
$35.00
Forecasted Upside/Downside
+58.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

Net Income
$-25,000,000.00
Pretax Margin
-1.14%

Debt

Sales & Book Value

Annual Sales
$463.93 million
Cash Flow
$8.19 per share
Book Value
$5.80 per share

Miscellaneous

Free Float
33,452,000
Market Cap
$776.22 million
Optionable
Optionable
Beta
0.84
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Michael Thomas Heffernan B.S. Pharm (Age 59)
    R.Ph., Co-Founder & Chairman
    Comp: $110k
  • Mr. Joseph J. CiaffoniMr. Joseph J. Ciaffoni (Age 52)
    Pres, CEO & Director
    Comp: $1.69M
  • Ms. Colleen TupperMs. Colleen Tupper (Age 47)
    Exec. VP & CFO
    Comp: $848.29k
  • Ms. Shirley R. KuhlmannMs. Shirley R. Kuhlmann (Age 39)
    Exec. VP, Gen. Counsel, Chief Admin. Officer & Sec.
    Comp: $842.9k
  • Mr. Scott DreyerMr. Scott Dreyer (Age 51)
    Exec. VP & Chief Commercial Officer
    Comp: $746.58k
  • Dr. Thomas B. Smith FAAFP (Age 62)
    M.D., Exec. VP & Chief Medical Officer
    Comp: $692.91k
  • Dr. Christopher Shayne James M.D.
    VP of Investor Relations
  • Mr. Bart J. Dunn
    Exec. VP of Strategy & Corp. Devel.
  • Mr. Scott Sudduth
    Head of Technical Operations













COLL Stock - Frequently Asked Questions

Should I buy or sell Collegium Pharmaceutical stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" COLL shares.
View COLL analyst ratings
or view top-rated stocks.

What is Collegium Pharmaceutical's stock price forecast for 2023?

2 Wall Street research analysts have issued 1-year price objectives for Collegium Pharmaceutical's stock. Their COLL share price forecasts range from $35.00 to $36.00. On average, they predict the company's share price to reach $35.50 in the next year. This suggests a possible upside of 58.8% from the stock's current price.
View analysts price targets for COLL
or view top-rated stocks among Wall Street analysts.

How have COLL shares performed in 2023?

Collegium Pharmaceutical's stock was trading at $23.20 at the beginning of the year. Since then, COLL stock has decreased by 3.7% and is now trading at $22.35.
View the best growth stocks for 2023 here
.

Are investors shorting Collegium Pharmaceutical?

Collegium Pharmaceutical saw a drop in short interest in September. As of September 15th, there was short interest totaling 6,920,000 shares, a drop of 6.5% from the August 31st total of 7,400,000 shares. Based on an average trading volume of 293,000 shares, the days-to-cover ratio is presently 23.6 days. Currently, 20.5% of the shares of the stock are sold short.
View Collegium Pharmaceutical's Short Interest
.

When is Collegium Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our COLL earnings forecast
.

How were Collegium Pharmaceutical's earnings last quarter?

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) announced its earnings results on Thursday, August, 3rd. The specialty pharmaceutical company reported $1.13 earnings per share for the quarter, beating analysts' consensus estimates of $1.11 by $0.02. The specialty pharmaceutical company had revenue of $135.55 million for the quarter, compared to the consensus estimate of $137.98 million. Collegium Pharmaceutical had a positive trailing twelve-month return on equity of 87.81% and a negative net margin of 2.08%.

What guidance has Collegium Pharmaceutical issued on next quarter's earnings?

Collegium Pharmaceutical issued an update on its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $565.00 million-$580.00 million, compared to the consensus revenue estimate of $570.46 million.

What is Joseph Ciaffoni's approval rating as Collegium Pharmaceutical's CEO?

6 employees have rated Collegium Pharmaceutical Chief Executive Officer Joseph Ciaffoni on Glassdoor.com. Joseph Ciaffoni has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Collegium Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Collegium Pharmaceutical investors own include Galapagos (GLPG), NVIDIA (NVDA), AbbVie (ABBV), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Pfizer (PFE), Bausch Health Companies (BHC), Gilead Sciences (GILD) and GW Pharmaceuticals (GWPH).

When did Collegium Pharmaceutical IPO?

(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at a price of $12.00-$14.00 per share. Jefferies and Piper Jaffray served as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.

What is Collegium Pharmaceutical's stock symbol?

Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."

How do I buy shares of Collegium Pharmaceutical?

Shares of COLL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Collegium Pharmaceutical's stock price today?

One share of COLL stock can currently be purchased for approximately $22.35.

How much money does Collegium Pharmaceutical make?

Collegium Pharmaceutical (NASDAQ:COLL) has a market capitalization of $776.22 million and generates $463.93 million in revenue each year. The specialty pharmaceutical company earns $-25,000,000.00 in net income (profit) each year or ($0.37) on an earnings per share basis.

How many employees does Collegium Pharmaceutical have?

The company employs 207 workers across the globe.

How can I contact Collegium Pharmaceutical?

Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The official website for the company is www.collegiumpharma.com. The specialty pharmaceutical company can be reached via phone at (781) 713-3699 or via email at info@collegiumpharma.com.

This page (NASDAQ:COLL) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -